Autopsy report · NCT05065619
Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）
Cause of deathStaffing, sites or logistics, also funding or business
“Public vaccination of approved ancestral strain COVID-19 vaccines will be terminated soon. And boosters must be dosed after ancestral vaccination approved in Japan. The study was terminated for ethical reason to prioritize the ancestral vaccination.”
Life of this trial
- Ran for about 1 year 4 months before it stopped.
- 128 participants enrolled.
- Results were posted on the registry 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Medicago
- Sponsor type
- Industry
- Conditions
- SARS-CoV-2 Infection
- Interventions
- MT-2766 High dose (3.75 µg); Placebo; MT-2766 Low dose
- Participants
- 128
- Sites
- 3
- Countries
- Japan
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.